Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer

Launched by UNC LINEBERGER COMPREHENSIVE CANCER CENTER · Nov 9, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new experimental treatment for lung cancer, specifically targeting patients with advanced small cell lung carcinoma or non-small cell lung cancer who have not responded to standard treatments. The treatment involves modifying a type of immune cell called T cells to better fight cancer cells. These modified T cells are designed to target a specific protein found on some cancer cells, which may help improve treatment outcomes for patients. The main goal of the trial is to determine how safe this new treatment is and to find the right dosage that patients can tolerate without experiencing serious side effects.

To be eligible for the trial, participants must be adults with a life expectancy of at least 12 weeks, have previously received certain cancer therapies, and must provide informed consent to participate. Patients will first have their blood drawn so that their T cells can be modified in the lab. After the cells are prepared, they will be given back to the patient. While this treatment is still experimental and not yet approved by health authorities, it offers a potential new option for individuals facing challenging lung cancer diagnoses.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Written informed consent to undergo cell procurement explained to, understood by, and signed by the subject.
• • 2. Subject has a life expectancy of ≥ 12 weeks.
• • 3. Subject must be platinum-refractory and either currently receiving or has previously received a PD1/PDL1 inhibitor
• • 4. Use of systemic corticosteroids at doses ≥10 mg prednisone daily or it's equivalent; those receiving \<10 mg daily may be enrolled at the discretion of the investigator.
• • 5. Female subjects of childbearing potential must have a negative serum pregnancy test within 72 hours prior to cell procurement.
• • 6. Subject has demonstrated adequate organ function.
• Exclusion Criteria:
• • 1 . Subject has less than 12 weeks of life expectancy.
• • 2. Subject did not receive platinum-based chemotherapy
• • 3. Subject does not have adequate organ function.